{"entity":{"id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","aka":["BEHOLD-Endometrial01"],"tldr":"A phase 3 trial of Doxorubicin in endometrial cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) is a phase 3 interventional study registered as NCT07286331 by GlaxoSmithKline, with 600 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-02-29. Interventions recorded: Mocertatug rezetecan, Paclitaxel and Doxorubicin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07286331","url":"https://clinicaltrials.gov/study/NCT07286331"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["doxorubicin"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07286331","phase":"3","setting":"A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT07286331","source":"https://clinicaltrials.gov/study/NCT07286331","fetchedAt":"2026-10-07T16:55:38.126Z","studySha256":"2b4c9b859a32412460bfcd521ffba13da8c9b9698e14ac905a3720331a126e97","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-02","leadSponsor":"GlaxoSmithKline","collaboratorCount":1,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":600,"enrolmentType":"ESTIMATED","siteCount":48,"recruitingSiteCount":48,"countries":["Argentina","Australia","Brazil","Canada","Israel","Japan","Panama","South Korea","United Kingdom","United States"]}],"started":"2026-06-04","startedType":"actual","enrolled":600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07286331/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}